Recent studies have focused on the use of CF patient organoids generated from primary intestinal, lung, and nasal epithelial cells as an approach to measure both patient and tissue-specific therapeutic responses of CFTR modulators17–19. The gene discussed is CFTR; the disease is cystic fibrosis.